denbufylline has been researched along with Lupus Erythematosus, Systemic in 1 studies
denbufylline: structure given in first source
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
Excerpt | Relevance | Reference |
---|---|---|
"Systemic lupus erythematosus is a polymorphic and multigenic inflammatory autoimmune disease." | 1.38 | Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor. ( Bourguignon, JJ; Gazi, L; Keravis, T; Lugnier, C; Monneaux, F; Muller, S; Yougbaré, I, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Keravis, T | 1 |
Monneaux, F | 1 |
Yougbaré, I | 1 |
Gazi, L | 1 |
Bourguignon, JJ | 1 |
Muller, S | 1 |
Lugnier, C | 1 |
1 other study available for denbufylline and Lupus Erythematosus, Systemic
Article | Year |
---|---|
Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor.
Topics: Adenine; Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Progression; Fem | 2012 |